SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
SHR-1210 is a humanized anti-PD1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an
open- label，single center ，non-randomized ，Single Arm Exploratory Study . This clinical study
is an investigator-initiatedclini-cal trial（IIT ）.The objective of this study is to evaluate
the efficacy and safety of adjuvant therapy with anti-PD-1 antibody SHR-1210 and apatinib in
patients with Barcelona Clinic Liver Cancer (BCLC) B&C stage hepatocellular carcinoma after
surgery.